Abstract: An anti-human papillomavirus (HPV) monoclonal antibody reactive with various types of HPVs, which is produced by a hybridoma comprising a fused cell of a mouse spleen cell from a mouse immunized with an alkali-treated HPV type 1 (HPV-1) and a mouse myeloma cell, and which is reactive with polypeptides of about 57 kilodaltons, about 160 kilodaltons and about 230 kilodaltons of HPV-1, and a process for preparing the same. The monoclonal antibody of the invention is reactive with various types of HPV and useful for diagnosis of various types of HPV infection (primary diagnosis).
Abstract: Monoclonal antibodies specific for an epitope found on hemoglobin glycated both in vivo and in vitro but not found on hemoglobin A.sub.o or hemoglobin A.sub.1c are provided. Use of these antibodies to measure glycohemoglobin levels in the blood provides a measure of the glucose levels in the erythrocyte for the previous 90-120 days. No reduction of the blood sample is required to produce the epitope recognized by the monoclonal antibodies.
Abstract: Analogs of Tyrosine Sulfate or Tyrosine Phosphate containing peptides, the novel intermediate compounds used in the preparation of these analogs, as well as a method for suppressing appetite in subjects by administering to the subject an effective amount of CCK analog wherein one or more of any Tyrosine Sulfate present is substituted with a radical of the invention.
Type:
Grant
Filed:
July 18, 1991
Date of Patent:
January 26, 1993
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Waleed Danho, Jefferson W. Tilley, Joseph Triscari, Rolf Wagner
Abstract: The present invention relates to a monoclonal antibody which is broadly reactive with all normal human peripheral blood mononuclear cells and granulocyte, and to the hybridoma cell line which produces this monoclonal antibody. This monoclonal antibody is designated WM-65 and the hybridoma cell line is designated F56-1D5 (ECACC 89033001). This monoclonal antibody reacts with a previously unrecognized human leucocyte surface membrane antigen. The relative molecular mass of the antigen recognized by WM-65 is approximately 40-50 Kilodaltons.
Type:
Grant
Filed:
November 21, 1990
Date of Patent:
January 12, 1993
Assignee:
Biomedical Systems Limited
Inventors:
Kenneth F. Bradstock, Michael K. Atkinson, Anthony J. Henniker
Abstract: The present invention is directed to new de-(acetylglucosaminyl)-di(dehydro)deoxy teicoplanin derivatives which possess antibiotic activity mainly against gram positive bacteria.The new compounds are obtained by chemical modification of a teicoplanin antibiotic substance.
Type:
Grant
Filed:
October 21, 1991
Date of Patent:
November 17, 1992
Assignee:
Gruppo Lepetit S.p.A.
Inventors:
Adriano Malabarba, Pietro Ferrari, Aldo Trani, Giorgio Tarzia
Abstract: Synthetic linear or cyclic peptides having the formula[A].sub.x -[B].sub.x -Ser-Ser-Ser-Asn-Tyr-[C].sub.xwhereinA is L-Ala, DL-Ala, D-Ala, Gly, or Val;B is L-Ala, DL-Ala, D-Ala, Gly, or Val;C is L-Met, L-Met (O), Cys, Thr or Gly; andx is an integer of from 0-1.A method of treating AIDS by administering the synthetic peptides is also provided.
Abstract: Novel peptides which exhibit inhibitory activity toward serine proteases and methods for preparing and using same are disclosed. In one aspect, the present invention provides peptides comprising a generic inhibitory core having a functional site recognition sequence fused to the N-terminus. The functional site recognition sequence is adapted to provide enhanced selectivity and/or potency for a target protease.
Abstract: Peptide analogues of human humoral hypercalcemic factor (hHCF) that contain a lactam bridge act as inhibitors of the naturally occurring peptide. A lactam bridge between Lys and Asp situated five residues (inclusive) apart confers rigidity to that region of the peptide, and enhances the helical nature and metabolic stability of the peptide analogue.
Abstract: Disclosed herein are cyclic peptide derivatives of the formula ##STR1## wherein A is absent or the tripeptide radical Thr.rarw.Gly.rarw.Ala, R.sup.1 is benzyl or benzyl monosubstituted at position 4 of the aromatic ring with halo, hydroxy, lower alkyl or lower alkoxy, R.sup.2 and R.sup.4 each independently is hydrogen or lower alkyl, R.sup.3 is lower alkyl or lower alkyl monosubstituted with a hydroxy, R.sup.5 is lower alkyl, Y is oxo or thioxo and Z is hydroxy or NR.sup.6 R.sup.7 wherein R.sup.6 and R.sup.7 each independently is hydrogen or lower alkyl. The derivatives are useful for treating herpes infections.
Type:
Grant
Filed:
July 3, 1990
Date of Patent:
September 22, 1992
Assignee:
Bio-Mega, Inc.
Inventors:
Julian Adams, John DiMaio, Raymond Plante
Abstract: A process for the manufacture of vancomycin which does not require preparation of a phosphate intermediate. The process consists of loading a vancomycin onto a suitable adsorbent and eluting the vancomycin solution therefrom with an ammonium solvent followed by loading the solution onto a second adsorbent and eluting the purified, vancomycin therefrom with a solvent of alcohol and acid. The purified vancomycin is then crystallized by adding a base solution in an amount sufficient to raise the pH of the vancomycin/base solution to a pH of about 9.5 to 10.5 followed by the addition of an organic solvent such as methanol. The crystallized vancomycin is then reslurried in an aqueous solution and then recrystallized by adding a base solution in an amount sufficient to raise the pH to about 9.5 to about 10.5, followed by the addition of an organic solvent such as methanol. The recrystallized vancomycin is dissolved and titrated with hydrochloric acid to a pH of about 3.0 to 3.5.
Abstract: Polypeptides corresponding in amino acid residue sequence to T cell stimulating regions of the HBV nucleocapsid protein are disclosed. A method of enhancing the immunogenicity of a polypeptide immunogen comprising operatively linking the polypeptide through an amino acid residue side chain to core protein particles is also disclosed.
Type:
Grant
Filed:
November 20, 1989
Date of Patent:
September 1, 1992
Assignee:
The Scripps Research Institute
Inventors:
George B. Thornton, Ann M. Moriarty, David R. Milich, Alan McLachlan
Abstract: A new and demonstratably active cyclo-octapeptide is isolated from the South Pacific Ocean Hymeniacidon sp. and structurally elucidated. The substance, herein denominated Hymenistatin 1, demonstrated utility by inhibiting tumor growth when measured by the National Cancer Institute P388 leukemia cell line (ED.sub.50 =3.5 .mu.g/mL).
Type:
Grant
Filed:
November 30, 1989
Date of Patent:
July 14, 1992
Assignee:
Arizona Board of Regents, a body corporate of Arizona State University
Abstract: A novel substance having anthelmintic activity, the PF 1022 substance, which is produced by cultivating a fungal strain capable of producing the substance and recovering the substance from the culture.